(seroma production,16.459626800144342)
(low-dose aspirin,14.108251542980867)
(post-diagnosis low-dose,11.756876285817388)
(patient prolactinoma,9.40550102865391)
(barcode mode,9.40550102865391)
(mri protocol,9.40550102865391)
(membrane type,9.40550102865391)
(patient diagnose,9.40550102865391)
(tnbc cell,9.40550102865391)
(pet imaging,9.40550102865391)
(contrast agent,8.291140383017662)
(increase risk,7.783640596221253)
(study report,7.054125771490433)
(breast lung,7.054125771490433)
(vitamin derivative,7.054125771490433)
(cxcr4-targeted pet,7.054125771490433)
(type breast,7.054125771490433)
(metastatic disease,7.054125771490433)
(age year,7.054125771490433)
(her2 breast,7.054125771490433)
(68ga-pentixafor pet,7.054125771490433)
(diagnose age,7.054125771490433)
(association post-diagnosis,7.054125771490433)
(breast neuroma,7.054125771490433)
(anti-her2 therapy,7.054125771490433)
(prognostic signature,7.054125771490433)
(abbreviated mri,7.054125771490433)
(shearlet transform,7.054125771490433)
(intake b-carotene,7.054125771490433)
(traumatic breast,7.054125771490433)
(infrare fluorescent,7.054125771490433)
(chest wall,5.8377304471659395)
(diagnose life,4.702750514326955)
(previous study,4.702750514326955)
(cancer detection,4.702750514326955)
(prolactinoma higher,4.702750514326955)
(wall lesion,4.702750514326955)
(patient distant,4.702750514326955)
(high diagnostic,4.702750514326955)
(18f-fdg pet,4.702750514326955)
(homologous recombination-mediated,4.702750514326955)
(treatment option,4.702750514326955)
(radiotherapy case,4.702750514326955)
(breast pain,4.702750514326955)
(case traumatic,4.702750514326955)
(human error,4.702750514326955)
(early diagnosis,4.702750514326955)
(cxcr4-directed pet,4.702750514326955)
(cancer intake,4.702750514326955)
(computer aid,4.702750514326955)
(contralateral breast,4.702750514326955)
(progression-free survival,4.702750514326955)
(cell vitro,4.702750514326955)
(signature prognostic,4.702750514326955)
(platinum salt,4.702750514326955)
(recombination-mediated dna,4.702750514326955)
(subtype-specific prognostic,4.702750514326955)
(benign lesion,4.702750514326955)
(cancer survivor,4.702750514326955)
(case invasive,4.702750514326955)
(completion radiotherapy,4.702750514326955)
(cancer visually,4.702750514326955)
(ctn biomarker,4.702750514326955)
(brcaness phenotype,4.702750514326955)
(higher family,4.702750514326955)
(patient receive,4.702750514326955)
(unknown primary,4.702750514326955)
(distant metastase,4.702750514326955)
(pathway component,4.702750514326955)
(factor seroma,4.702750514326955)
(third-degree relative,4.702750514326955)
(locally-advanced breast,4.702750514326955)
(member report,4.702750514326955)
(systemic therapy,4.702750514326955)
(diagnostic accuracy,4.702750514326955)
(vivo msot,4.702750514326955)
(personal cancer,4.702750514326955)
(variation seroma,4.702750514326955)
(month completion,4.702750514326955)
(assess diet,4.702750514326955)
(history cancer,4.702750514326955)
(patient primary,4.702750514326955)
(derivative breast,4.702750514326955)
(summary hazard,4.702750514326955)
(disease presentation,4.702750514326955)
(value-based healthcare,4.702750514326955)
(locoregional progression-free,4.702750514326955)
(aid diagnosis,4.702750514326955)
(cancer family,4.702750514326955)
(cell bet,4.702750514326955)
(glycosylation site,4.702750514326955)
(traumatic neuroma,4.702750514326955)
(dietary intake,4.702750514326955)
(observe variation,4.702750514326955)
(ejection fraction,4.702750514326955)
(neuropathic breast,4.702750514326955)
(imaging patient,4.702750514326955)
(intake vitamin,4.702750514326955)
(tumour shrinkage,4.702750514326955)
(molecular subtype,4.702750514326955)
(osteopontin-based probe,4.702750514326955)
(second third-degree,4.702750514326955)
(visually detectable,4.702750514326955)
(imaging modality,4.702750514326955)
(diet diagnosis,4.702750514326955)
(survival patient,4.702750514326955)
(hormonal contraception,4.702750514326955)
(fluorescent imaging,4.702750514326955)
(brca1 wild-type,4.702750514326955)
(risk cbc,4.702750514326955)
(aspirin risk,4.702750514326955)
(pituitary adenoma,4.702750514326955)
(bet inhibitor,4.702750514326955)
(screening behavior,4.702750514326955)
(multimodal contrast,4.702750514326955)
(hazard ratio,3.8918202981106265)
(cancer receive,3.8918202981106265)
(patient history,3.8918202981106265)
(family member,3.8918202981106265)
(patient breast,3.316456153207065)
(primary breast,3.316456153207065)
(cancer patient,2.505525936990736)
(necessity consider,2.3513752571634776)
(potential aion,2.3513752571634776)
(death united,2.3513752571634776)
(understand filipino,2.3513752571634776)
(cell brd4,2.3513752571634776)
(previous breastaxillary,2.3513752571634776)
(positive family,2.3513752571634776)
(finally novel,2.3513752571634776)
(promise advanced,2.3513752571634776)
(additional indicator,2.3513752571634776)
(rna inhibitor,2.3513752571634776)
(exhibit suvmax,2.3513752571634776)
(diagnosis conclusion,2.3513752571634776)
(cancer better,2.3513752571634776)
(near-infrared fluorophore,2.3513752571634776)
(anthracycline elderly,2.3513752571634776)
(history breast-conserving,2.3513752571634776)
(filter help,2.3513752571634776)
(cbc nationwide,2.3513752571634776)
(fill follow-up,2.3513752571634776)
(shrinkage occur,2.3513752571634776)
(nationwide registry,2.3513752571634776)
(detection outperform,2.3513752571634776)
(result occurrence,2.3513752571634776)
(dermatitis median,2.3513752571634776)
(cardiac dysfunction,2.3513752571634776)
(option neoadjuvant,2.3513752571634776)
(involve regulate,2.3513752571634776)
(extra-terminal protein,2.3513752571634776)
(cancer play,2.3513752571634776)
(outcome cost,2.3513752571634776)
(accurate 93.45,2.3513752571634776)
(profile patient,2.3513752571634776)
(high specificity,2.3513752571634776)
(exam appealing,2.3513752571634776)
(quality appropriateness,2.3513752571634776)
(age patient,2.3513752571634776)
(rare benign,2.3513752571634776)
(patient specific,2.3513752571634776)
(base transform,2.3513752571634776)
(include estrogen,2.3513752571634776)
(screening study,2.3513752571634776)
(sentence fuckasdgahaaetk,2.3513752571634776)
(greater tumor,2.3513752571634776)
(small patient,2.3513752571634776)
(tumor bed,2.3513752571634776)
(emerge precise,2.3513752571634776)
(conclusion finding,2.3513752571634776)
(clinician exploit,2.3513752571634776)
(utilize classify,2.3513752571634776)
(report imaging,2.3513752571634776)
(shared genetic,2.3513752571634776)
(good negative,2.3513752571634776)
(expenditure healthcare,2.3513752571634776)
(frequently overexpress,2.3513752571634776)
(salt parp,2.3513752571634776)
(prognosis patient,2.3513752571634776)
(measure wound,2.3513752571634776)
(registry main,2.3513752571634776)
(presence metastatic,2.3513752571634776)
(wane time,2.3513752571634776)
(visually undetectable,2.3513752571634776)
(effective efficient,2.3513752571634776)
(undergo cxcr4-targeted,2.3513752571634776)
(patient study,2.3513752571634776)
(breast self-examination,2.3513752571634776)
(intake breast,2.3513752571634776)
(human rapidly,2.3513752571634776)
(factor corresponding,2.3513752571634776)
(small contour,2.3513752571634776)
(mammographic image,2.3513752571634776)
(result indicate,2.3513752571634776)
(follow platinum,2.3513752571634776)
(sulfide nanoparticle,2.3513752571634776)
(protocol reflect,2.3513752571634776)
(therapy radiotherapy,2.3513752571634776)
(severe reduction,2.3513752571634776)
(median bmi,2.3513752571634776)
(cycle regulator,2.3513752571634776)
(ctn level,2.3513752571634776)
(effective diagnosis,2.3513752571634776)
(unusual physical,2.3513752571634776)
(woman improve,2.3513752571634776)
(history intractable,2.3513752571634776)
(vitro vivo,2.3513752571634776)
(treatment cancer,2.3513752571634776)
(multivariate analysis,2.3513752571634776)
(post-injection signal,2.3513752571634776)
(screening tool,2.3513752571634776)
(wall disease,2.3513752571634776)
(surgery metastatic,2.3513752571634776)
(shearlet coefficient,2.3513752571634776)
(screening woman,2.3513752571634776)
(gene involve,2.3513752571634776)
(cohort cxcr4-targeted,2.3513752571634776)
(near-infrared fluorescence,2.3513752571634776)
(suitable algorithm,2.3513752571634776)
(remain main,2.3513752571634776)
(imaging feature,2.3513752571634776)
(association dietary,2.3513752571634776)
(clinical study,2.3513752571634776)
(brca1 presence,2.3513752571634776)
(older strong,2.3513752571634776)
(perform breast,2.3513752571634776)
(clinic perform,2.3513752571634776)
(multiple study,2.3513752571634776)
(neoadjuvant anti-her2,2.3513752571634776)
(healthcare define,2.3513752571634776)
(routinely implement,2.3513752571634776)
(interestingly triple,2.3513752571634776)
(patient labc,2.3513752571634776)
(finances cancer,2.3513752571634776)
(lowest intake,2.3513752571634776)
(study provide,2.3513752571634776)
(surgery rare,2.3513752571634776)
(0.93 gday,2.3513752571634776)
(stage iii,2.3513752571634776)
(12.1 patient,2.3513752571634776)
(patient previous,2.3513752571634776)
(signaling pathway,2.3513752571634776)
(remove lymph,2.3513752571634776)
(association intake,2.3513752571634776)
(physical finding,2.3513752571634776)
(treatment cbc,2.3513752571634776)
(supplement vitamin,2.3513752571634776)
(highest versus,2.3513752571634776)
(result association,2.3513752571634776)
(role palliative,2.3513752571634776)
(treatment finally,2.3513752571634776)
(4.8 year,2.3513752571634776)
(biomarker derive,2.3513752571634776)
(help detect,2.3513752571634776)
(specific population,2.3513752571634776)
(malignancy diagnose,2.3513752571634776)
(strategy base,2.3513752571634776)
(plan at-risk,2.3513752571634776)
(association ctn,2.3513752571634776)
(hospital ulm,2.3513752571634776)
(neuroma postmenopausal,2.3513752571634776)
(regulator dna,2.3513752571634776)
(death worldwide,2.3513752571634776)
(total cancer,2.3513752571634776)
(summarize representative,2.3513752571634776)
(protocol reproducibility,2.3513752571634776)
(model identify,2.3513752571634776)
(rapid resolution,2.3513752571634776)
(replace fee-for-service,2.3513752571634776)
(enhancement image,2.3513752571634776)
(receive neoadjuvant,2.3513752571634776)
(case twenty-six,2.3513752571634776)
(serum membrane,2.3513752571634776)
(osteopontin-750 probe,2.3513752571634776)
(receive external,2.3513752571634776)
(higher risk,2.3513752571634776)
(disease variable,2.3513752571634776)
(factor include,2.3513752571634776)
(prolactinoma breast,2.3513752571634776)
(stratification acute,2.3513752571634776)
(imaging method,2.3513752571634776)
(continue promote,2.3513752571634776)
(article protect,2.3513752571634776)
(production type,2.3513752571634776)
(regulation aim,2.3513752571634776)
(tumor 9.7,2.3513752571634776)
(treat high,2.3513752571634776)
(novel clinical,2.3513752571634776)
(cancer case,2.3513752571634776)
(review conduct,2.3513752571634776)
(cardiotoxicity patient,2.3513752571634776)
(examination mri,2.3513752571634776)
(erbb family,2.3513752571634776)
(wavelet base,2.3513752571634776)
(cohort result,2.3513752571634776)
(estimate random,2.3513752571634776)
(article aim,2.3513752571634776)
(injection study,2.3513752571634776)
(framework analyze,2.3513752571634776)
(contrast-enhanced screening,2.3513752571634776)
(contrast injection,2.3513752571634776)
(metastase presentation,2.3513752571634776)
(acromegaly lung,2.3513752571634776)
(tumor triple-negative,2.3513752571634776)
(cancer genetic,2.3513752571634776)
(rate novel,2.3513752571634776)
(harmless tissue,2.3513752571634776)
(pet correlation,2.3513752571634776)
(breast-conserving surgery,2.3513752571634776)
(risk cardiovascular,2.3513752571634776)
(background association,2.3513752571634776)
(efficient techniqueus,2.3513752571634776)
(genetic susceptibility,2.3513752571634776)
(proportion patient,2.3513752571634776)
(negative predictive,2.3513752571634776)
(cardiovascular injury,2.3513752571634776)
(primary undergo,2.3513752571634776)
(rule recurrent,2.3513752571634776)
(dual approach,2.3513752571634776)
(view current,2.3513752571634776)
(assume membrane,2.3513752571634776)
(lesion report,2.3513752571634776)
(application preventive,2.3513752571634776)
(type hormone,2.3513752571634776)
(disease locoregional,2.3513752571634776)
(segmentation algorithm,2.3513752571634776)
(neoadjuvant chemotherapy,2.3513752571634776)
(express type,2.3513752571634776)
(inhibitor compound,2.3513752571634776)
(better outcome,2.3513752571634776)
(cancer conservative,2.3513752571634776)
(woman perceive,2.3513752571634776)
(sensitivity myocardial,2.3513752571634776)
(disease control,2.3513752571634776)
(affect cancer,2.3513752571634776)
(b-carotene associate,2.3513752571634776)
(aion form,2.3513752571634776)
(fee-for-service model,2.3513752571634776)
(digital breast,2.3513752571634776)
(cancer highly,2.3513752571634776)
(serve motivation,2.3513752571634776)
(therapy receive,2.3513752571634776)
(factor breast,2.3513752571634776)
(member affect,2.3513752571634776)
(aion negligible,2.3513752571634776)
(conclusion large,2.3513752571634776)
(decade advance,2.3513752571634776)
(breastaxillary surgery,2.3513752571634776)
(radiotherapy seroma,2.3513752571634776)
(tumor nude,2.3513752571634776)
(higher patient,2.3513752571634776)
(clinic year,2.3513752571634776)
(involve cancer,2.3513752571634776)
(symptom control,2.3513752571634776)
(cancer invasive,2.3513752571634776)
(grade radiation,2.3513752571634776)
(axillary lymph,2.3513752571634776)
(outperform conventional,2.3513752571634776)
(pet prognostic,2.3513752571634776)
(anti-her2 treatment,2.3513752571634776)
(transform multiresolution,2.3513752571634776)
(human early,2.3513752571634776)
(patient lapatinib,2.3513752571634776)
(determine multiple,2.3513752571634776)
(vivo provide,2.3513752571634776)
(cancer assume,2.3513752571634776)
(risk provide,2.3513752571634776)
(year previous,2.3513752571634776)
(longer duration,2.3513752571634776)
(increase contrast,2.3513752571634776)
(small advance,2.3513752571634776)
(retrospective chart,2.3513752571634776)
(locally advanced,2.3513752571634776)
(surgery four-month,2.3513752571634776)
(image segmentation,2.3513752571634776)
(interview conduct,2.3513752571634776)
(31.12.2014 breast,2.3513752571634776)
(case include,2.3513752571634776)
(analyze 2016,2.3513752571634776)
(serum detect,2.3513752571634776)
(target immune,2.3513752571634776)
(patient axillary,2.3513752571634776)
(surgery consider,2.3513752571634776)
(cancer-specific survival,2.3513752571634776)
(cancer second,2.3513752571634776)
(conduct systemic,2.3513752571634776)
(year disease,2.3513752571634776)
(antibody small,2.3513752571634776)
(diagnose early-onset,2.3513752571634776)
(accumulation fluorescent,2.3513752571634776)
(inconsistent result,2.3513752571634776)
(barrier difficulty,2.3513752571634776)
(tumour biology,2.3513752571634776)
(lobular carcinoma,2.3513752571634776)
(discovery independent,2.3513752571634776)
(induce brcaness,2.3513752571634776)
(perception screening,2.3513752571634776)
(biomarker patient,2.3513752571634776)
(subtype attempt,2.3513752571634776)
(lesion measure,2.3513752571634776)
(objective breast,2.3513752571634776)
(corresponding cohort,2.3513752571634776)
(cancer presentation,2.3513752571634776)
(maker focus,2.3513752571634776)
(induce chemotherapy,2.3513752571634776)
(appealing high,2.3513752571634776)
(behavior guide,2.3513752571634776)
(consultation better,2.3513752571634776)
(survivor provide,2.3513752571634776)
(monitoring chemotherapy,2.3513752571634776)
(bet inhibition,2.3513752571634776)
(responsible death,2.3513752571634776)
(delay radiotherapy,2.3513752571634776)
(year compare,2.3513752571634776)
(follow-up apply,2.3513752571634776)
(factor association,2.3513752571634776)
(mannose receptor,2.3513752571634776)
(inconsistent conduct,2.3513752571634776)
(involve gene,2.3513752571634776)
(concurrently anthracycline,2.3513752571634776)
(brd4 find,2.3513752571634776)
(combine capecitabine,2.3513752571634776)
(evaluation cardiotoxicity,2.3513752571634776)
(factor enable,2.3513752571634776)
(specific cancer,2.3513752571634776)
(rights reserve,2.3513752571634776)
(strong evidence,2.3513752571634776)
(cancer personal,2.3513752571634776)
(site base,2.3513752571634776)
(explain small,2.3513752571634776)
(cardiac biomarker,2.3513752571634776)
(cell noteworthy,2.3513752571634776)
(explore novel,2.3513752571634776)
(detect normal,2.3513752571634776)
(accord preliminary,2.3513752571634776)
(cancer clustering,2.3513752571634776)
(tumor detectability,2.3513752571634776)
(selective binding,2.3513752571634776)
(personal perceive,2.3513752571634776)
(strategy analyze,2.3513752571634776)
(extent apparent,2.3513752571634776)
(silver ion,2.3513752571634776)
(base barcode,2.3513752571634776)
(organ confirm,2.3513752571634776)
(form co-encapsulation,2.3513752571634776)
(regulation homologous,2.3513752571634776)
(prospective retrospective,2.3513752571634776)
(finding consistently,2.3513752571634776)
(observational study,2.3513752571634776)
(diagnostic tool,2.3513752571634776)
(conventional x-ray,2.3513752571634776)
(fluorophore silver,2.3513752571634776)
(breast cancer-specific,2.3513752571634776)
(neoadjuvant systemic,2.3513752571634776)
(surgical side,2.3513752571634776)
(multiple factor,2.3513752571634776)
(united states,2.3513752571634776)
(atechnique aid,2.3513752571634776)
(perform inception,2.3513752571634776)
(case analyze,2.3513752571634776)
(well history,2.3513752571634776)
(concept fast,2.3513752571634776)
(user longer,2.3513752571634776)
(analyze thematic,2.3513752571634776)
(wider population,2.3513752571634776)
(specificity high,2.3513752571634776)
(formulation effective,2.3513752571634776)
(protocol utility,2.3513752571634776)
(approach inquiry,2.3513752571634776)
(mri technique,2.3513752571634776)
(representative gene-expression-based,2.3513752571634776)
(compare 18f-fdg,2.3513752571634776)
(cancer study,2.3513752571634776)
(cancer female,2.3513752571634776)
(pet image,2.3513752571634776)
(one-year exposure,2.3513752571634776)
(cancer cell-related,2.3513752571634776)
(embase perform,2.3513752571634776)
(carcinogenesis clinical,2.3513752571634776)
(examination concern,2.3513752571634776)
(acquisition interpretation,2.3513752571634776)
(receptor highly,2.3513752571634776)
(preclinical phase,2.3513752571634776)
(meta-analysis dietary,2.3513752571634776)
(stage disease,2.3513752571634776)
(personal theory,2.3513752571634776)
(meet inclusion,2.3513752571634776)
(study indicate,2.3513752571634776)
(agent detection,2.3513752571634776)
(image visually,2.3513752571634776)
(facilitate diagnosis,2.3513752571634776)
(cancer vulnerability,2.3513752571634776)
(population breast,2.3513752571634776)
(tumor grade,2.3513752571634776)
(imaging disease,2.3513752571634776)
(protocol introduce,2.3513752571634776)
(surgery length,2.3513752571634776)
(result forty-three,2.3513752571634776)
(report risk,2.3513752571634776)
(dose adjuvant,2.3513752571634776)
(length surgery,2.3513752571634776)
(consider traumatic,2.3513752571634776)
(patient survival,2.3513752571634776)
(development tool,2.3513752571634776)
(patient strong,2.3513752571634776)
(improved breast,2.3513752571634776)
(mechanism carcinogenesis,2.3513752571634776)
(couple possibility,2.3513752571634776)
(woman record,2.3513752571634776)
(cost limit,2.3513752571634776)
(noteworthy strategy,2.3513752571634776)
(subtype 18f-fdg,2.3513752571634776)
(cancer human,2.3513752571634776)
(iii breast,2.3513752571634776)
(iort patient,2.3513752571634776)
(systemnumber processing,2.3513752571634776)
(study assess,2.3513752571634776)
(standardized imaging,2.3513752571634776)
(case report,2.3513752571634776)
(pain high,2.3513752571634776)
(improve biocompatibility,2.3513752571634776)
(biology treatment,2.3513752571634776)
(indicate subtype-specific,2.3513752571634776)
(signature strong,2.3513752571634776)
(diagnosis meta-regression,2.3513752571634776)
(prospective study,2.3513752571634776)
(analysis result,2.3513752571634776)
(definitive diagnosis,2.3513752571634776)
(production primary,2.3513752571634776)
(tool target,2.3513752571634776)
(brca1 addition,2.3513752571634776)
(decrease mortality,2.3513752571634776)
(disease choice,2.3513752571634776)
(therapy surgery,2.3513752571634776)
(review meta-analysis,2.3513752571634776)
(alternative contrast-enhanced,2.3513752571634776)
(pill find,2.3513752571634776)
(will aid,2.3513752571634776)
(prescription fill,2.3513752571634776)
(identify clearly,2.3513752571634776)
(patient year,2.3513752571634776)
(diagnosis implement,2.3513752571634776)
(reduction brca1,2.3513752571634776)
(trigger synthetic,2.3513752571634776)
(image enhancement,2.3513752571634776)
(novel target,2.3513752571634776)
(identify thesuspicious,2.3513752571634776)
(tumor-specific imaging,2.3513752571634776)
(patient pituitary,2.3513752571634776)
(tend compare,2.3513752571634776)
(correlation suvmax,2.3513752571634776)
(probe identify,2.3513752571634776)
(set confirm,2.3513752571634776)
(address cancer,2.3513752571634776)
(collect family,2.3513752571634776)
(promote quality,2.3513752571634776)
(trastuzumab identification,2.3513752571634776)
(factor will,2.3513752571634776)
(include erbb,2.3513752571634776)
(radiologist result,2.3513752571634776)
(cancer recognize,2.3513752571634776)
(tracer accumulation,2.3513752571634776)
(transtuzumab-induced cardiac,2.3513752571634776)
(relative report,2.3513752571634776)
(strong family,2.3513752571634776)
(non-ideal safety,2.3513752571634776)
(broader population,2.3513752571634776)
(percent patient,2.3513752571634776)
(prolactinoma family,2.3513752571634776)
(expression confirm,2.3513752571634776)
(confirm bet,2.3513752571634776)
(benefit cardiotoxicity,2.3513752571634776)
(management locally-advanced,2.3513752571634776)
(production 82.5,2.3513752571634776)
(primary cancer,2.3513752571634776)
(triple-negative breast,2.3513752571634776)
(diagnosis cardiotoxicity,2.3513752571634776)
(cardiotoxicity main,2.3513752571634776)
(member rasmapk,2.3513752571634776)
(nfpa patient,2.3513752571634776)
(healthcare paradigm,2.3513752571634776)
(understanding factor,2.3513752571634776)
(number imagesneed,2.3513752571634776)
(limited evidence,2.3513752571634776)
(radiation dermatitis,2.3513752571634776)
(user result,2.3513752571634776)
(tumor site,2.3513752571634776)
(mammography underutilize,2.3513752571634776)
(elderly patient,2.3513752571634776)
(year forty-two,2.3513752571634776)
(93.45 utilize,2.3513752571634776)
(surveillance therapeutic,2.3513752571634776)
(mri nirf,2.3513752571634776)
(rare case,2.3513752571634776)
(properly select,2.3513752571634776)
(serve high-risk,2.3513752571634776)
(compare sister,2.3513752571634776)
(cancer current,2.3513752571634776)
(synthetic lethality,2.3513752571634776)
(process address,2.3513752571634776)
(yield case,2.3513752571634776)
(small imaging,2.3513752571634776)
(anthracycline study,2.3513752571634776)
(therapy precision,2.3513752571634776)
(investigate breast,2.3513752571634776)
(assessment response,2.3513752571634776)
(contribution radiology,2.3513752571634776)
(sister diagnose,2.3513752571634776)
(patient anti-her2,2.3513752571634776)
(serve contrast,2.3513752571634776)
(improve screening,2.3513752571634776)
(aspirin estrogen,2.3513752571634776)
(involve neoadjuvant,2.3513752571634776)
(clear extent,2.3513752571634776)
(background cxcr4,2.3513752571634776)
(chemokine receptor,2.3513752571634776)
(precise tool,2.3513752571634776)
(time medical,2.3513752571634776)
(lack finances,2.3513752571634776)
(intake 0.93,2.3513752571634776)
(regression model,2.3513752571634776)
(proliferation tumor,2.3513752571634776)
(paper propose,2.3513752571634776)
(prediction specific,2.3513752571634776)
(pathway inhibition,2.3513752571634776)
(long noncoding,2.3513752571634776)
(aid radiologist,2.3513752571634776)
(behavior factor,2.3513752571634776)
(identify study,2.3513752571634776)
(optoacoustic tomography,2.3513752571634776)
(compare pathological,2.3513752571634776)
(mammography digital,2.3513752571634776)
(prognosis prediction,2.3513752571634776)
(rise healthcare,2.3513752571634776)
(cancer overcome,2.3513752571634776)
(increase scrutiny,2.3513752571634776)
(cancer large,2.3513752571634776)
(risk screening,2.3513752571634776)
(generate strong,2.3513752571634776)
(agent non-ideal,2.3513752571634776)
(median age,2.3513752571634776)
(concern gadolinium-based,2.3513752571634776)
(strong independent,2.3513752571634776)
(issue imaging,2.3513752571634776)
(msot imaging,2.3513752571634776)
(shrinkage prior,2.3513752571634776)
(interval estimate,2.3513752571634776)
(modality simplify,2.3513752571634776)
(locus control,2.3513752571634776)
(utilize ddsm,2.3513752571634776)
(probe potent,2.3513752571634776)
(liver 2.5,2.3513752571634776)
(lesion surgical,2.3513752571634776)
(contraception find,2.3513752571634776)
(patient demographic,2.3513752571634776)
(apply identify,2.3513752571634776)
(risk levonorgestrel,2.3513752571634776)
(disease primary,2.3513752571634776)
(signal accumulation,2.3513752571634776)
(inheritance locus,2.3513752571634776)
(differentially express,2.3513752571634776)
(protect copyright,2.3513752571634776)
(multi-omic profile,2.3513752571634776)
(record primary,2.3513752571634776)
(dem mri,2.3513752571634776)
(25.6 kgm2,2.3513752571634776)
(magn reson,2.3513752571634776)
(strategy andor,2.3513752571634776)
(cancer survival,2.3513752571634776)
(type mass,2.3513752571634776)
(cancer barcode,2.3513752571634776)
(therapy patient,2.3513752571634776)
(filipino woman,2.3513752571634776)
(duration breast,2.3513752571634776)
(recovery delay,2.3513752571634776)
(andor regional,2.3513752571634776)
(urgently accord,2.3513752571634776)
(inhibitors-based treatment,2.3513752571634776)
(review yield,2.3513752571634776)
(negative her2,2.3513752571634776)
(production conclusion,2.3513752571634776)
(combination pharmacological,2.3513752571634776)
(ability prognosis,2.3513752571634776)
(separately assess,2.3513752571634776)
(compare tumor,2.3513752571634776)
(material method,2.3513752571634776)
(highly express,2.3513752571634776)
(biomarker breast,2.3513752571634776)
(factor patient,2.3513752571634776)
(aim collect,2.3513752571634776)
(cell overcome,2.3513752571634776)
(fluorescent dye,2.3513752571634776)
(relapse year,2.3513752571634776)
(cancer cohort,2.3513752571634776)
(imaging 68ga-pentixafor,2.3513752571634776)
(incorporate experience,2.3513752571634776)
(study wane,2.3513752571634776)
(treatment stage,2.3513752571634776)
(prolonged recovery,2.3513752571634776)
(3.5 18f-fdg,2.3513752571634776)
(novel all-in-one,2.3513752571634776)
(group database,2.3513752571634776)
(expression metastase,2.3513752571634776)
(implement computer,2.3513752571634776)
(brd4 brca1rad51,2.3513752571634776)
(evidence technical,2.3513752571634776)
(diagnosis urgently,2.3513752571634776)
(imagesneed examine,2.3513752571634776)
(diagnosis range,2.3513752571634776)
(surgery intervention,2.3513752571634776)
(healthcare expenditure,2.3513752571634776)
(fast abbreviated,2.3513752571634776)
(generally reserve,2.3513752571634776)
(radiotherapy provide,2.3513752571634776)
(therapeutic benefit,2.3513752571634776)
(test breast,2.3513752571634776)
(trastuzumab-induced severe,2.3513752571634776)
(brca1rad51 expression,2.3513752571634776)
(invasive breast,2.3513752571634776)
(exist contrast,2.3513752571634776)
(techniqueus detection,2.3513752571634776)
(disease lung,2.3513752571634776)
(dce-mri broader,2.3513752571634776)
(cbc identify,2.3513752571634776)
(abbreviated fast,2.3513752571634776)
(emerge role,2.3513752571634776)
(reproducibility study,2.3513752571634776)
(energy mammography,2.3513752571634776)
(metastase recurrent,2.3513752571634776)
(study aspirin,2.3513752571634776)
(type pa.,2.3513752571634776)
(total patient,2.3513752571634776)
(protein historically,2.3513752571634776)
(thesuspicious region,2.3513752571634776)
(evidence association,2.3513752571634776)
(compute tomography,2.3513752571634776)
(b-carotene woman,2.3513752571634776)
(age onset,2.3513752571634776)
(cxcr4 chemokine,2.3513752571634776)
(amount observe,2.3513752571634776)
(hazard regression,2.3513752571634776)
(identification cardiotoxicity,2.3513752571634776)
(2012 drug,2.3513752571634776)
(policy maker,2.3513752571634776)
(imaging near-infrared,2.3513752571634776)
(msot secondary,2.3513752571634776)
(cancer age,2.3513752571634776)
(study initial,2.3513752571634776)
(imaging technique,2.3513752571634776)
(medical consultation,2.3513752571634776)
(family nfpa,2.3513752571634776)
(analyze glycosylation,2.3513752571634776)
(bleed improve,2.3513752571634776)
(probe accumulate,2.3513752571634776)
(seek understand,2.3513752571634776)
(discuss management,2.3513752571634776)
(suitable general,2.3513752571634776)
(15.3 patient,2.3513752571634776)
(side result,2.3513752571634776)
(time high,2.3513752571634776)
(good response,2.3513752571634776)
(comprehensive search,2.3513752571634776)
(diagnosis month,2.3513752571634776)
(osteopontin target,2.3513752571634776)
(clustering patient,2.3513752571634776)
(molecule inhibitor,2.3513752571634776)
(parp inhibitors-based,2.3513752571634776)
(nationwide cohort,2.3513752571634776)
(cooperative group,2.3513752571634776)
(directional sensitive,2.3513752571634776)
(maximum standardized,2.3513752571634776)
(main evidence,2.3513752571634776)
(disease characteristic,2.3513752571634776)
(meta-regression analysis,2.3513752571634776)
(develop multimodal,2.3513752571634776)
(role signaling,2.3513752571634776)
(patient stratify,2.3513752571634776)
(assess brd4,2.3513752571634776)
(patient negative,2.3513752571634776)
(computational framework,2.3513752571634776)
(provide inconsistent,2.3513752571634776)
(metastasis unknown,2.3513752571634776)
(semi-quantitatively comparison,2.3513752571634776)
(correlation aforementioned,2.3513752571634776)
(regional lymph,2.3513752571634776)
(option method,2.3513752571634776)
(newly identify,2.3513752571634776)
(cardiotoxicity appear,2.3513752571634776)
(immunohistochemistry perform,2.3513752571634776)
(functional breast,2.3513752571634776)
(result consistent,2.3513752571634776)
(overexpress invasive,2.3513752571634776)
(neuroma accurate,2.3513752571634776)
(multiresolution result,2.3513752571634776)
(issue exist,2.3513752571634776)
(initial result,2.3513752571634776)
(reveal observe,2.3513752571634776)
(phase crucial,2.3513752571634776)
(nac iort,2.3513752571634776)
(gene-expression-based prognostic,2.3513752571634776)
(algorithm apply,2.3513752571634776)
(normal human,2.3513752571634776)
(profile aion,2.3513752571634776)
(base drug,2.3513752571634776)
(tomography selective,2.3513752571634776)
(limit widespread,2.3513752571634776)
(patient develop,2.3513752571634776)
(cancer describe,2.3513752571634776)
(patient woman,2.3513752571634776)
(analyze cross-sectional,2.3513752571634776)
(recombination pathway,2.3513752571634776)
(directionality shift,2.3513752571634776)
(prognostic prediction,2.3513752571634776)
(intervention exclude,2.3513752571634776)
(case compare,2.3513752571634776)
(error visual,2.3513752571634776)
(prior surgery,2.3513752571634776)
(indicator mutational,2.3513752571634776)
(history trastuzumab-induced,2.3513752571634776)
(ctn validate,2.3513752571634776)
(status proliferation,2.3513752571634776)
(woman female,2.3513752571634776)
(survivor serve,2.3513752571634776)
(age diagnosis,2.3513752571634776)
(consistently find,2.3513752571634776)
(model examine,2.3513752571634776)
(death trigger,2.3513752571634776)
(lead massive,2.3513752571634776)
(subcutaneous breast,2.3513752571634776)
(timing diagnosis,2.3513752571634776)
(find associate,2.3513752571634776)
(propose shearlet,2.3513752571634776)
(precision medicine,2.3513752571634776)
(difficulty allot,2.3513752571634776)
(specific subgroup,2.3513752571634776)
(lead cardiotoxicity,2.3513752571634776)
(chemotherapy cardiac,2.3513752571634776)
(resolution chest,2.3513752571634776)
(role value-based,2.3513752571634776)
(mastectomy literature,2.3513752571634776)
(pursue preventive,2.3513752571634776)
(finding limited,2.3513752571634776)
(select case,2.3513752571634776)
(anthracycline treatment,2.3513752571634776)
(follow radiotherapy,2.3513752571634776)
(demonstrate phantom,2.3513752571634776)
(cytotoxicity agreement,2.3513752571634776)
(observe substantial,2.3513752571634776)
(involve dna,2.3513752571634776)
(diagnosis risk,2.3513752571634776)
(fatigue.in order,2.3513752571634776)
(network classifier,2.3513752571634776)
(radiotherapy applicable,2.3513752571634776)
(derivative associate,2.3513752571634776)
(model result,2.3513752571634776)
(impair ability,2.3513752571634776)
(time greater,2.3513752571634776)
(locoregional radiotherapy,2.3513752571634776)
(underline necessity,2.3513752571634776)
(independent data,2.3513752571634776)
(tnbc associate,2.3513752571634776)
(improve breast,2.3513752571634776)
(preferentially subcutaneous,2.3513752571634776)
(patient positive,2.3513752571634776)
(imaging vivo,2.3513752571634776)
(forty-three case,2.3513752571634776)
(asymptomatic neuroma,2.3513752571634776)
(population patient,2.3513752571634776)
(develop cbc,2.3513752571634776)
(causation personalistic,2.3513752571634776)
(report type,2.3513752571634776)
(vivo tumor,2.3513752571634776)
(neural network,2.3513752571634776)
(reflect increase,2.3513752571634776)
(diagnosis systemnumber,2.3513752571634776)
(contraception user,2.3513752571634776)
(overcome limitation,2.3513752571634776)
(notably collect,2.3513752571634776)
(uptake tumor-to-background,2.3513752571634776)
(tomography magnetic,2.3513752571634776)
(treatment wider,2.3513752571634776)
(analysis assess,2.3513752571634776)
(diagnosis year,2.3513752571634776)
(aim overview,2.3513752571634776)
(administration osteopontin-750,2.3513752571634776)
(diagnosis surveillance,2.3513752571634776)
(all-in-one nanoparticle,2.3513752571634776)
(hinder homologous,2.3513752571634776)
(enable clinician,2.3513752571634776)
(18f-fdg petct,2.3513752571634776)
(cancer method,2.3513752571634776)
(cxcr4 expression,2.3513752571634776)
(cell immune,2.3513752571634776)
(progesterone receptor,2.3513752571634776)
(treatment conjugate,2.3513752571634776)
(distinguish type,2.3513752571634776)
(oxide nanoparticle,2.3513752571634776)
(result alternative,2.3513752571634776)
(increment intake,2.3513752571634776)
(reveal respondent,2.3513752571634776)
(lower compare,2.3513752571634776)
(history age,2.3513752571634776)
(capecitabine result,2.3513752571634776)
(four-month history,2.3513752571634776)
(confirm result,2.3513752571634776)
(therapeutic model,2.3513752571634776)
(distinguish barcode,2.3513752571634776)
(define patient,2.3513752571634776)
(control deterioration,2.3513752571634776)
(detection emerge,2.3513752571634776)
(disease fatal,2.3513752571634776)
(result misdiagnosis,2.3513752571634776)
(cxcr4 imaging,2.3513752571634776)
(finding well,2.3513752571634776)
(fast breast,2.3513752571634776)
(node metastasis,2.3513752571634776)
(classify mammographic,2.3513752571634776)
(suvmax 68ga-pentixafor,2.3513752571634776)
(collect signature,2.3513752571634776)
(9.7 time,2.3513752571634776)
(metastase involve,2.3513752571634776)
(perceive barrier,2.3513752571634776)
(colorectal cancer,2.3513752571634776)
(dose duration,2.3513752571634776)
(intrauterine system-both,2.3513752571634776)
(cxcr4-targeted tracer,2.3513752571634776)
(production breast,2.3513752571634776)
(practice study,2.3513752571634776)
(surgery number,2.3513752571634776)
(cancer relative,2.3513752571634776)
(patient outcome,2.3513752571634776)
(molecular mechanism,2.3513752571634776)
(cancer future,2.3513752571634776)
(signature originally,2.3513752571634776)
(improve follow,2.3513752571634776)
(radiotherapy locoregional,2.3513752571634776)
(level evidence,2.3513752571634776)
(utility breast,2.3513752571634776)
(recurrent disease,2.3513752571634776)
(history female,2.3513752571634776)
(model limit,2.3513752571634776)
(image development,2.3513752571634776)
(intractable neuropathic,2.3513752571634776)
(cancer complex,2.3513752571634776)
(negligible cytotoxicity,2.3513752571634776)
(detection screening,2.3513752571634776)
(establish base,2.3513752571634776)
(accumulate preferentially,2.3513752571634776)
(originally target,2.3513752571634776)
(report 12.1,2.3513752571634776)
(cbc associate,2.3513752571634776)
(patient worldwide,2.3513752571634776)
(secondary confirmation,2.3513752571634776)
(breast axilla,2.3513752571634776)
(cancer cxcr4-targeted,2.3513752571634776)
(cancer shearlet,2.3513752571634776)
(nude mouse,2.3513752571634776)
(suspicion require,2.3513752571634776)
(technique require,2.3513752571634776)
(diagnose earlier,2.3513752571634776)
(clinical entity,2.3513752571634776)
(case underline,2.3513752571634776)
(factor address,2.3513752571634776)
(mri exam,2.3513752571634776)
(aforementioned prognostic,2.3513752571634776)
(paradigm replace,2.3513752571634776)
(identify subtype-specific,2.3513752571634776)
(maintain high,2.3513752571634776)
(osteopontin-750 accumulation,2.3513752571634776)
(vulnerability subjective,2.3513752571634776)
(woman responsible,2.3513752571634776)
(result ten,2.3513752571634776)
(pathway involve,2.3513752571634776)
(trial article,2.3513752571634776)
(identification prognostic,2.3513752571634776)
(history malignancy,2.3513752571634776)
(major role,2.3513752571634776)
(increase total,2.3513752571634776)
(system-both finding,2.3513752571634776)
(focus curb,2.3513752571634776)
(high-dose radiotherapy,2.3513752571634776)
(lapatinib combine,2.3513752571634776)
(cohort patient,2.3513752571634776)
(fatal disease,2.3513752571634776)
(cancercell small,2.3513752571634776)
(conclusion cxcr4-directed,2.3513752571634776)
(develop abbreviated,2.3513752571634776)
(avoid human,2.3513752571634776)
(evidence inverse,2.3513752571634776)
(twenty-six patient,2.3513752571634776)
(probe tumor,2.3513752571634776)
(typical signature,2.3513752571634776)
(component include,2.3513752571634776)
(seek develop,2.3513752571634776)
(strong association,2.3513752571634776)
(diagnostic imaging,2.3513752571634776)
(micelle aion,2.3513752571634776)
(option monoclonal,2.3513752571634776)
(refractory neuropathic,2.3513752571634776)
(relate better,2.3513752571634776)
(feasible properly,2.3513752571634776)
(patient cohort,2.3513752571634776)
(lesion include,2.3513752571634776)
(ethinyl estradiol,2.3513752571634776)
(flow cytometry,2.3513752571634776)
(lead decrease,2.3513752571634776)
(radiation primary,2.3513752571634776)
(apply clinical,2.3513752571634776)
(advanced imaging,2.3513752571634776)
(tumor patient,2.3513752571634776)
(time long,2.3513752571634776)
(reduction cardiac,2.3513752571634776)
(breast sensitive,2.3513752571634776)
(larger prospective,2.3513752571634776)
(mass spectrometry,2.3513752571634776)
(receive nac,2.3513752571634776)
(general diagnostic,2.3513752571634776)
(imaging aion,2.3513752571634776)
(contrast property,2.3513752571634776)
(commonly diagnose,2.3513752571634776)
(change aggressive,2.3513752571634776)
(cancer conclusion,2.3513752571634776)
(background management,2.3513752571634776)
(invasive disease,2.3513752571634776)
(investigate mutation,2.3513752571634776)
(meta-analysis summarize,2.3513752571634776)
(unenhanced mri,2.3513752571634776)
(study barcode,2.3513752571634776)
(experience breast,2.3513752571634776)
(transform detail,2.3513752571634776)
(carcinoma special,2.3513752571634776)
(transferable enable,2.3513752571634776)
(calculate hazard,2.3513752571634776)
(woman currently,2.3513752571634776)
(copyright rights,2.3513752571634776)
(conjugate osteopontin,2.3513752571634776)
(implement screening,2.3513752571634776)
(study cardiotoxicity,2.3513752571634776)
(mutational status,2.3513752571634776)
(diagnosis prognosis,2.3513752571634776)
(shift invariance,2.3513752571634776)
(suvmax 3.5,2.3513752571634776)
(modality specific,2.3513752571634776)
(inhibition induce,2.3513752571634776)
(interpretation time,2.3513752571634776)
(woman increase,2.3513752571634776)
(treatment feasible,2.3513752571634776)
(states death,2.3513752571634776)
(detectionof breast,2.3513752571634776)
(rapidly transferable,2.3513752571634776)
(trend radical,2.3513752571634776)
(worldwide year,2.3513752571634776)
(relative patient,2.3513752571634776)
(investigation breast,2.3513752571634776)
(target population,2.3513752571634776)
(andor early,2.3513752571634776)
(agreement minimal,2.3513752571634776)
(type differentially,2.3513752571634776)
(sample woman,2.3513752571634776)
(rasmapk pathway,2.3513752571634776)
(grade molecular,2.3513752571634776)
(treatment cardiac,2.3513752571634776)
(conclusion factor,2.3513752571634776)
(combination trastuzumab,2.3513752571634776)
(involve metastasis,2.3513752571634776)
(benign classification,2.3513752571634776)
(clearly distinguish,2.3513752571634776)
(population tnbc,2.3513752571634776)
(outpatient clinic,2.3513752571634776)
(centre university,2.3513752571634776)
(region result,2.3513752571634776)
(malign benign,2.3513752571634776)
(imaging study,2.3513752571634776)
(lag cox,2.3513752571634776)
(transform image,2.3513752571634776)
(importantly patient,2.3513752571634776)
(apply one-year,2.3513752571634776)
(recurrent her2,2.3513752571634776)
(appropriateness imaging,2.3513752571634776)
(tumor signal,2.3513752571634776)
(component brca1,2.3513752571634776)
(inception january,2.3513752571634776)
(worldwide discovery,2.3513752571634776)
(imaging suitable,2.3513752571634776)
(injury induce,2.3513752571634776)
(heterogeneous cancer,2.3513752571634776)
(ddsm database,2.3513752571634776)
(provide good,2.3513752571634776)
(experience live,2.3513752571634776)
(breast result,2.3513752571634776)
(improve therapy,2.3513752571634776)
(diagnosis process,2.3513752571634776)
(cell cycle,2.3513752571634776)
(design predict,2.3513752571634776)
(anthracycline combination,2.3513752571634776)
(aspirin 0.91,2.3513752571634776)
(regulate gene,2.3513752571634776)
(high-resolution image,2.3513752571634776)
(compare 68ga-pentixafor,2.3513752571634776)
(stratify base,2.3513752571634776)
(presentation relapse,2.3513752571634776)
(advanced breast,2.3513752571634776)
(follow systemic,2.3513752571634776)
(small molecule,2.3513752571634776)
(gene investigate,2.3513752571634776)
(patient discomfort,2.3513752571634776)
(feasible tumor,2.3513752571634776)
(iort explain,2.3513752571634776)
(patient recurrent,2.3513752571634776)
(woman breast,2.3513752571634776)
(january 2018,2.3513752571634776)
(image acquisition,2.3513752571634776)
(tomosynthesis ultrasound,2.3513752571634776)
(update risk,2.3513752571634776)
(site identify,2.3513752571634776)
(cbc median,2.3513752571634776)
(myocardial injury,2.3513752571634776)
(excision definitive,2.3513752571634776)
(major concern,2.3513752571634776)
(hormone receptor,2.3513752571634776)
(large nationwide,2.3513752571634776)
(control sister,2.3513752571634776)
(sensitive test,2.3513752571634776)
(study association,2.3513752571634776)
(aion effective,2.3513752571634776)
(12-15 tumor,2.3513752571634776)
(target therapeutic,2.3513752571634776)
(routine clinical,2.3513752571634776)
(rare clinical,2.3513752571634776)
(report higher,2.3513752571634776)
(result rapid,2.3513752571634776)
(parp inhibitor,2.3513752571634776)
(image suitable,2.3513752571634776)
(term hormonal,2.3513752571634776)
(association prediagnosis,2.3513752571634776)
(axilla result,2.3513752571634776)
(identify flow,2.3513752571634776)
(neuroma patient,2.3513752571634776)
(agent unenhanced,2.3513752571634776)
(patient relapse,2.3513752571634776)
(tnbc additional,2.3513752571634776)
(wavelet filter,2.3513752571634776)
(survival material,2.3513752571634776)
(invasive lobular,2.3513752571634776)
(relapse disease,2.3513752571634776)
(cancer chest,2.3513752571634776)
(fuckasdgahaaetk despite,2.3513752571634776)
(body mass,2.3513752571634776)
(relationship accumulate,2.3513752571634776)
(pet demonstrate,2.3513752571634776)
(conservative treatment,2.3513752571634776)
(forty-two percent,2.3513752571634776)
(intake assess,2.3513752571634776)
(mode type,2.3513752571634776)
(advance timing,2.3513752571634776)
(monoclonal antibody,2.3513752571634776)
(treat 01.01.2010,2.3513752571634776)
(nontarget organ,2.3513752571634776)
(identification evaluation,2.3513752571634776)
(summarize result,2.3513752571634776)
(liver fluorescence,2.3513752571634776)
(compare semi-quantitatively,2.3513752571634776)
(feature indicative,2.3513752571634776)
(inquiry face-to-face,2.3513752571634776)
(immune cell,2.3513752571634776)
(brd4 regulation,2.3513752571634776)
(ultrasound long,2.3513752571634776)
(negative family,2.3513752571634776)
(drug human,2.3513752571634776)
(demonstrate higher,2.3513752571634776)
(radiotherapy breast,2.3513752571634776)
(cbc risk,2.3513752571634776)
(contour enhancement,2.3513752571634776)
(strategy combination,2.3513752571634776)
(cardiac troponin,2.3513752571634776)
(result reveal,2.3513752571634776)
(adjusted cbc,2.3513752571634776)
(46.6 patient,2.3513752571634776)
(nirf contrast,2.3513752571634776)
(duration increase,2.3513752571634776)
(prognostic risk,2.3513752571634776)
(sampling case,2.3513752571634776)
(nac median,2.3513752571634776)
(co-encapsulation near-infrared,2.3513752571634776)
(pharmacological inhibition,2.3513752571634776)
(treat patient,2.3513752571634776)
(gene expression,2.3513752571634776)
(current hormonal,2.3513752571634776)
(0.70 highest,2.3513752571634776)
(assess ability,2.3513752571634776)
(protein directly,2.3513752571634776)
(systematically analyze,2.3513752571634776)
(differential diagnosis,2.3513752571634776)
(seroma formation,2.3513752571634776)
(cohort typical,2.3513752571634776)
(surveillance assessment,2.3513752571634776)
(intrinsic subtype,2.3513752571634776)
(mri breast,2.3513752571634776)
(cancer numerous,2.3513752571634776)
(pet probe,2.3513752571634776)
(2018 summary,2.3513752571634776)
(identify preventive,2.3513752571634776)
(median locoregional,2.3513752571634776)
(drug model,2.3513752571634776)
(conclusion multi-scale,2.3513752571634776)
(patient non-functioning,2.3513752571634776)
(bromodomain extra-terminal,2.3513752571634776)
(tumor-to-background ratio,2.3513752571634776)
(measure compare,2.3513752571634776)
(danish cohort,2.3513752571634776)
(production extent,2.3513752571634776)
(cancer unknown,2.3513752571634776)
(at-risk woman,2.3513752571634776)
(pegylate micelle,2.3513752571634776)
(preventive drug,2.3513752571634776)
(production remain,2.3513752571634776)
(high sensitivity,2.3513752571634776)
(year median,2.3513752571634776)
(cardiotoxicity ctn,2.3513752571634776)
(view personal,2.3513752571634776)
(external beam,2.3513752571634776)
(receive treatment,2.3513752571634776)
(diagnosis clear,2.3513752571634776)
(demonstrate bind,2.3513752571634776)
(ctn preclinical,2.3513752571634776)
(member apoptosis,2.3513752571634776)
(stage magn,2.3513752571634776)
(risk current,2.3513752571634776)
(surgery refractory,2.3513752571634776)
(female sibling,2.3513752571634776)
(classification accurate,2.3513752571634776)
(conclusion radiotherapy,2.3513752571634776)
(coefficient directional,2.3513752571634776)
(determine immunohistochemistry,2.3513752571634776)
(node patient,2.3513752571634776)
(family impact,2.3513752571634776)
(comparison cxcr4,2.3513752571634776)
(cox proportional,2.3513752571634776)
(microrna inhibitormimic,2.3513752571634776)
(confirmation signal,2.3513752571634776)
(attempt identify,2.3513752571634776)
(scrutiny disproportionate,2.3513752571634776)
(association prolactinoma,2.3513752571634776)
(imaging investigation,2.3513752571634776)
(propose atechnique,2.3513752571634776)
(allot time,2.3513752571634776)
(aion allow,2.3513752571634776)
(model calculate,2.3513752571634776)
(2.5 post-injection,2.3513752571634776)
(cardiotoxicity major,2.3513752571634776)
(human serum,2.3513752571634776)
(small amount,2.3513752571634776)
(database 2012,2.3513752571634776)
(distinguish subtype,2.3513752571634776)
(develop treatment,2.3513752571634776)
(datum discover,2.3513752571634776)
(wild-type triple,2.3513752571634776)
(bind breast,2.3513752571634776)
(therapeutic option,2.3513752571634776)
(imaging mammography,2.3513752571634776)
(time-varying post-diagnosis,2.3513752571634776)
(acute coronary,2.3513752571634776)
(68ga-pentixafor maximum,2.3513752571634776)
(patient intrinsic,2.3513752571634776)
(multimodal imaging,2.3513752571634776)
(01.01.2010 31.12.2014,2.3513752571634776)
(family patient,2.3513752571634776)
(dynamic contrast-enhanced,2.3513752571634776)
(duration treatment,2.3513752571634776)
(examine radiologist,2.3513752571634776)
(algorithm method,2.3513752571634776)
(low diagnostic,2.3513752571634776)
(allow vivo,2.3513752571634776)
(altogether study,2.3513752571634776)
(overcome increase,2.3513752571634776)
(cornerstone value-based,2.3513752571634776)
(ctn routine,2.3513752571634776)
(dense breast,2.3513752571634776)
(literature traumatic,2.3513752571634776)
(literature review,2.3513752571634776)
(development tnbc,2.3513752571634776)
(inhibitor altogether,2.3513752571634776)
(diagnose breast,2.3513752571634776)
(cancer development,2.3513752571634776)
(presentation patient,2.3513752571634776)
(disease relapse,2.3513752571634776)
(increase dna,2.3513752571634776)
(biomarker contribute,2.3513752571634776)
(result small,2.3513752571634776)
(range imaging,2.3513752571634776)
(despite trend,2.3513752571634776)
(complete radiotherapy,2.3513752571634776)
(radiotherapy generally,2.3513752571634776)
(prognostic separately,2.3513752571634776)
(difficult identify,2.3513752571634776)
(patient compare,2.3513752571634776)
(recognize heterogeneous,2.3513752571634776)
(current user,2.3513752571634776)
(marked reduction,2.3513752571634776)
(consistent previous,2.3513752571634776)
(current development,2.3513752571634776)
(tumour-related symptom,2.3513752571634776)
(age transcript,2.3513752571634776)
(higher suvmax,2.3513752571634776)
(cancer treatment,2.3513752571634776)
(status contralateral,2.3513752571634776)
(cytometry infrare,2.3513752571634776)
(risk small,2.3513752571634776)
(currently routinely,2.3513752571634776)
(breast tumor,2.3513752571634776)
(expression brd4,2.3513752571634776)
(screening mammography,2.3513752571634776)
(subjective risk,2.3513752571634776)
(mutation gene,2.3513752571634776)
(amount seroma,2.3513752571634776)
(brca1 rad51,2.3513752571634776)
(release profile,2.3513752571634776)
(introduce cxcr4-targeted,2.3513752571634776)
(coronary syndrome,2.3513752571634776)
(crispr-cas9-based gene,2.3513752571634776)
(low treat,2.3513752571634776)
(year chest,2.3513752571634776)
(data set,2.3513752571634776)
(main analysis,2.3513752571634776)
(immune checkpoint,2.3513752571634776)
(screen early,2.3513752571634776)
(checkpoint inhibitory,2.3513752571634776)
(homologous recombination,2.3513752571634776)
(generate brcaness,2.3513752571634776)
(study standardized,2.3513752571634776)
(aid formulation,2.3513752571634776)
(association vitamin,2.3513752571634776)
(pa. patient,2.3513752571634776)
(site vitro,2.3513752571634776)
(find increase,2.3513752571634776)
(provide update,2.3513752571634776)
(ratio 0.70,2.3513752571634776)
(cardiotoxicity monitoring,2.3513752571634776)
(main surgical,2.3513752571634776)
(examination screening,2.3513752571634776)
(beam radiotherapy,2.3513752571634776)
(25-30 breast,2.3513752571634776)
(visual fatigue.in,2.3513752571634776)
(inhibition bet,2.3513752571634776)
(deterioration ejection,2.3513752571634776)
(clinical behavior,2.3513752571634776)
(aion generate,2.3513752571634776)
(development target,2.3513752571634776)
(predispose gene,2.3513752571634776)
(subtype breast,2.3513752571634776)
(imaging demonstrate,2.3513752571634776)
(cell-related component,2.3513752571634776)
(examine association,2.3513752571634776)
(fear lack,2.3513752571634776)
(call crispr-cas9-based,2.3513752571634776)
(control patient,2.3513752571634776)
(imaging triple,2.3513752571634776)
(breast caner,2.3513752571634776)
(young patient,2.3513752571634776)
(extract utilize,2.3513752571634776)
(year adjusted,2.3513752571634776)
(appear direct,2.3513752571634776)
(screening diagnosis,2.3513752571634776)
(motivation perform,2.3513752571634776)
(combine parp,2.3513752571634776)
(diagnosis apply,2.3513752571634776)
(diffusion-weighted imaging,2.3513752571634776)
(widespread currently,2.3513752571634776)
(cancer introduce,2.3513752571634776)
(mastectomy patient,2.3513752571634776)
(accurate tissue,2.3513752571634776)
(associate mutation,2.3513752571634776)
(address issue,2.3513752571634776)
(derive cardiac,2.3513752571634776)
(case ulceration,2.3513752571634776)
(occur month,2.3513752571634776)
(decade development,2.3513752571634776)
(contribute early,2.3513752571634776)
(regulate homologous,2.3513752571634776)
(breast examination,2.3513752571634776)
(accomplish x-ray,2.3513752571634776)
(study ctn,2.3513752571634776)
(management discuss,2.3513752571634776)
(common agent,2.3513752571634776)
(tnbc patient,2.3513752571634776)
(cancer change,2.3513752571634776)
(mortality rate,2.3513752571634776)
(low ctn,2.3513752571634776)
(base result,2.3513752571634776)
(accumulation infrare,2.3513752571634776)
(prognosis number,2.3513752571634776)
(analysis image,2.3513752571634776)
(noncoding rna,2.3513752571634776)
(latest treatment,2.3513752571634776)
(additional anti-her2,2.3513752571634776)
(predictive conclusion,2.3513752571634776)
(osteopontin peptide,2.3513752571634776)
(self-examination clinical,2.3513752571634776)
(cancer cooperative,2.3513752571634776)
(receptor frequently,2.3513752571634776)
(chemotherapy remain,2.3513752571634776)
(detectable case,2.3513752571634776)
(purposively sample,2.3513752571634776)
(cancer summary,2.3513752571634776)
(lead improve,2.3513752571634776)
(2005-2017 46.6,2.3513752571634776)
(moist desquamation,2.3513752571634776)
(phenotype tnbc,2.3513752571634776)
(scan time,2.3513752571634776)
(repair complex,2.3513752571634776)
(analysis define,2.3513752571634776)
(aggressive course,2.3513752571634776)
(signal nontarget,2.3513752571634776)
(safety issue,2.3513752571634776)
(presence predispose,2.3513752571634776)
(medicine patient,2.3513752571634776)
(cancer accomplish,2.3513752571634776)
(limit nontarget,2.3513752571634776)
(complex heterogeneous,2.3513752571634776)
(binding osteopontin-based,2.3513752571634776)
(dual energy,2.3513752571634776)
(nanoparticle pegylate,2.3513752571634776)
(type distinguish,2.3513752571634776)
(disproportionate contribution,2.3513752571634776)
(repair generate,2.3513752571634776)
(early detection,2.3513752571634776)
(sensitive wavelet,2.3513752571634776)
(history transtuzumab-induced,2.3513752571634776)
(year second,2.3513752571634776)
(woman incorporate,2.3513752571634776)
(clinical breast,2.3513752571634776)
(healthcare policy,2.3513752571634776)
(variation accord,2.3513752571634776)
(impact woman,2.3513752571634776)
(bmi 25.6,2.3513752571634776)
(clinical strategy,2.3513752571634776)
(associate survival,2.3513752571634776)
(prolactinoma commonly,2.3513752571634776)
(lethality combine,2.3513752571634776)
(20-mcg ethinyl,2.3513752571634776)
(cardiac disease,2.3513752571634776)
(nanoparticle iron,2.3513752571634776)
(conduct purposively,2.3513752571634776)
(cancer higher,2.3513752571634776)
(future cxcr4,2.3513752571634776)
(evidence low,2.3513752571634776)
(prognosis assess,2.3513752571634776)
(kgm2 patient,2.3513752571634776)
(tissue sampling,2.3513752571634776)
(brcaness brca1,2.3513752571634776)
(review literature,2.3513752571634776)
(consider latest,2.3513752571634776)
(estradiol pill,2.3513752571634776)
(classifier conclusion,2.3513752571634776)
(construct view,2.3513752571634776)
(radiologist diagnosis,2.3513752571634776)
(ondata phase,2.3513752571634776)
(tissue neural,2.3513752571634776)
(reserve management,2.3513752571634776)
(remain anthracycline,2.3513752571634776)
(mammography compute,2.3513752571634776)
(life breast,2.3513752571634776)
(specific application,2.3513752571634776)
(result generate,2.3513752571634776)
(sister construct,2.3513752571634776)
(unresected locally-advanced,2.3513752571634776)
(receive iort,2.3513752571634776)
(follow-up 4.8,2.3513752571634776)
(b-carotene breast,2.3513752571634776)
(median amount,2.3513752571634776)
(application e.g.,2.3513752571634776)
(type mannose,2.3513752571634776)
(chemotherapy intra-operative,2.3513752571634776)
(consultation fear,2.3513752571634776)
(require lesion,2.3513752571634776)
(pubmed embase,2.3513752571634776)
(selective accumulation,2.3513752571634776)
(mammography low,2.3513752571634776)
(large cohort,2.3513752571634776)
(independent prognostic,2.3513752571634776)
(remain unresectable,2.3513752571634776)
(treatment breast,2.3513752571634776)
(diagnosis family,2.3513752571634776)
(case exhibit,2.3513752571634776)
(contrast-enhanced mri,2.3513752571634776)
(development improve,2.3513752571634776)
(damage regulation,2.3513752571634776)
(patient characteristic,2.3513752571634776)
(adenoma outpatient,2.3513752571634776)
(numerous gene-expression-based,2.3513752571634776)
(approach direct,2.3513752571634776)
(random model,2.3513752571634776)
(result vivo,2.3513752571634776)
(discover membrane,2.3513752571634776)
(outcome estrogen,2.3513752571634776)
(provide strong,2.3513752571634776)
(detectability lower,2.3513752571634776)
(cancer determine,2.3513752571634776)
(target probe,2.3513752571634776)
(early-onset breast,2.3513752571634776)
(iron oxide,2.3513752571634776)
(positive breast,2.3513752571634776)
(undetectable lesion,2.3513752571634776)
(relapse her2,2.3513752571634776)
(transtuzumab disease,2.3513752571634776)
(demographic disease,2.3513752571634776)
(exposure lead,2.3513752571634776)
(curb advanced,2.3513752571634776)
(fraction discuss,2.3513752571634776)
(fraction receive,2.3513752571634776)
(non-functioning pituitary,2.3513752571634776)
(result prolonged,2.3513752571634776)
(conduct patient,2.3513752571634776)
(repair pathway,2.3513752571634776)
(effective multimodal,2.3513752571634776)
(shape belief,2.3513752571634776)
(university hospital,2.3513752571634776)
(find involve,2.3513752571634776)
(cell death,2.3513752571634776)
(vitro osteopontin-750,2.3513752571634776)
(formation measure,2.3513752571634776)
(68ga-pentixafor result,2.3513752571634776)
(cancer feasible,2.3513752571634776)
(2016 median,2.3513752571634776)
(risk pursue,2.3513752571634776)
(neuroma breast,2.3513752571634776)
(signature computational,2.3513752571634776)
(bed kidney,2.3513752571634776)
(wall andor,2.3513752571634776)
(damage follow,2.3513752571634776)
(imaging examination,2.3513752571634776)
(cancer difficult,2.3513752571634776)
(effective management,2.3513752571634776)
(analysis adjustment,2.3513752571634776)
(cardiotoxicity diagnosis,2.3513752571634776)
(aspirin breast,2.3513752571634776)
(stratification lead,2.3513752571634776)
(diagnostic performance,2.3513752571634776)
(biocompatibility aion,2.3513752571634776)
(carcinoma case,2.3513752571634776)
(exploit platinum,2.3513752571634776)
(target treatment,2.3513752571634776)
(express breast,2.3513752571634776)
(inhibitormimic immunotherapy-based,2.3513752571634776)
(cancer spite,2.3513752571634776)
(feasible offer,2.3513752571634776)
(evidence increase,2.3513752571634776)
(analysis seroma,2.3513752571634776)
(complex process,2.3513752571634776)
(technique diffusion-weighted,2.3513752571634776)
(early identification,2.3513752571634776)
(originally design,2.3513752571634776)
(patient colorectal,2.3513752571634776)
(disease unusual,2.3513752571634776)
(report mastectomy,2.3513752571634776)
(clinical biomarker,2.3513752571634776)
(case asymptomatic,2.3513752571634776)
(adoption ctn,2.3513752571634776)
(immunotherapy-based approach,2.3513752571634776)
(dose anthracycline,2.3513752571634776)
(criterion median,2.3513752571634776)
(brd4 pharmacological,2.3513752571634776)
(earlier age,2.3513752571634776)
(diagnosis rule,2.3513752571634776)
(method towavelet,2.3513752571634776)
(enhancement method,2.3513752571634776)
(primary tumour,2.3513752571634776)
(cancer danish,2.3513752571634776)
(molecular biology,2.3513752571634776)
(overexpress 25-30,2.3513752571634776)
(management recurrent,2.3513752571634776)
(possibility marked,2.3513752571634776)
(study summarize,2.3513752571634776)
(occurrence contralateral,2.3513752571634776)
(imaging breast,2.3513752571634776)
(improve detection,2.3513752571634776)
(novel powerful,2.3513752571634776)
(discovery biomarker,2.3513752571634776)
(ulm perform,2.3513752571634776)
(e.g. therapeutic,2.3513752571634776)
(abbreviate dynamic,2.3513752571634776)
(neuroma rare,2.3513752571634776)
(imaging probe,2.3513752571634776)
(therapy change,2.3513752571634776)
(tool imaging,2.3513752571634776)
(inhibitor induce,2.3513752571634776)
(semi-structured interview,2.3513752571634776)
(receptor progesterone,2.3513752571634776)
(sibling diagnose,2.3513752571634776)
(experience grade,2.3513752571634776)
(subtype observe,2.3513752571634776)
(search pubmed,2.3513752571634776)
(mammography effective,2.3513752571634776)
(invasive carcinoma,2.3513752571634776)
(sister cancer,2.3513752571634776)
(technique call,2.3513752571634776)
(entity case,2.3513752571634776)
(editing emerge,2.3513752571634776)
(inverse association,2.3513752571634776)
(historically involve,2.3513752571634776)
(syndrome ctn,2.3513752571634776)
(pain diagnostic,2.3513752571634776)
(tumor lesion,2.3513752571634776)
(dietary supplement,2.3513752571634776)
(report increase,2.3513752571634776)
(diagnosis study,2.3513752571634776)
(assess diagnostic,2.3513752571634776)
(require additional,2.3513752571634776)
(cross-sectional prospective,2.3513752571634776)
(evaluate vivo,2.3513752571634776)
(reduction cost,2.3513752571634776)
(presentation tumour,2.3513752571634776)
(cancer tnbc,2.3513752571634776)
(radical surgical,2.3513752571634776)
(level hinder,2.3513752571634776)
(result feature,2.3513752571634776)
(lesion small,2.3513752571634776)
(apply early,2.3513752571634776)
(understanding tumour,2.3513752571634776)
(neuroma differential,2.3513752571634776)
(nontarget toxicity,2.3513752571634776)
(caner severe,2.3513752571634776)
(massive cell,2.3513752571634776)
(multi-scale shearlet,2.3513752571634776)
(pharmacological induction,2.3513752571634776)
(patient diagnosis,2.3513752571634776)
(result total,2.3513752571634776)
(generate malign,2.3513752571634776)
(intra-operative radiotherapy,2.3513752571634776)
(associate 20-mcg,2.3513752571634776)
(cancer systematically,2.3513752571634776)
(process involve,2.3513752571634776)
(cancer multispectral,2.3513752571634776)
(accord pattern,2.3513752571634776)
(palliative radiotherapy,2.3513752571634776)
(induce dose-dependent,2.3513752571634776)
(patient serum,2.3513752571634776)
(year 2005-2017,2.3513752571634776)
(standardized uptake,2.3513752571634776)
(wound drain,2.3513752571634776)
(result familial,2.3513752571634776)
(accumulation base,2.3513752571634776)
(suvmax patient,2.3513752571634776)
(cancer notably,2.3513752571634776)
(salt exposure,2.3513752571634776)
(provide high-resolution,2.3513752571634776)
(aim retrospective,2.3513752571634776)
(order avoid,2.3513752571634776)
(cancer shared,2.3513752571634776)
(ability tnbc,2.3513752571634776)
(phenomenological approach,2.3513752571634776)
(compare patient,2.3513752571634776)
(study seek,2.3513752571634776)
(powerful technique,2.3513752571634776)
(versus lowest,2.3513752571634776)
(accuracy couple,2.3513752571634776)
(study investigate,2.3513752571634776)
(investigate woman,2.3513752571634776)
(perceive risk,2.3513752571634776)
(diagnosis larger,2.3513752571634776)
(face-to-face semi-structured,2.3513752571634776)
(outcome good,2.3513752571634776)
(study aim,2.3513752571634776)
(agent novel,2.3513752571634776)
(tool dual,2.3513752571634776)
(biology experiment,2.3513752571634776)
(breast imaging,2.3513752571634776)
(risk associate,2.3513752571634776)
(base glycosylation,2.3513752571634776)
(management tumour-related,2.3513752571634776)
(model level,2.3513752571634776)
(chart review,2.3513752571634776)
(epigenetic brcaness,2.3513752571634776)
(intensity tumor,2.3513752571634776)
(experiment datum,2.3513752571634776)
(inhibition impair,2.3513752571634776)
(adjuvant transtuzumab,2.3513752571634776)
(demonstrate selective,2.3513752571634776)
(treatment anthracycline,2.3513752571634776)
(exposure lag,2.3513752571634776)
(patient mastectomy,2.3513752571634776)
(study adoption,2.3513752571634776)
(confirm subtype-specific,2.3513752571634776)
(efficacy stage,2.3513752571634776)
(drug tumor,2.3513752571634776)
(relative cancer,2.3513752571634776)
(guide phenomenological,2.3513752571634776)
(patient family,2.3513752571634776)
(woman 12-15,2.3513752571634776)
(prediction originally,2.3513752571634776)
(approach develop,2.3513752571634776)
(choice anti-her2,2.3513752571634776)
(surgery radiation,2.3513752571634776)
(advanced diagnostic,2.3513752571634776)
(trial practice,2.3513752571634776)
(ratio tumor,2.3513752571634776)
(vitro intravenous,2.3513752571634776)
(associate post-diagnosis,2.3513752571634776)
(processing analysis,2.3513752571634776)
(gday increment,2.3513752571634776)
(counseling consultation,2.3513752571634776)
(expression determine,2.3513752571634776)
(0.91 observe,2.3513752571634776)
(overview abbreviated,2.3513752571634776)
(postmenopausal patient,2.3513752571634776)
(belief regard,2.3513752571634776)
(transcript analyze,2.3513752571634776)
(burden experience,2.3513752571634776)
(result abbreviated,2.3513752571634776)
(shorten image,2.3513752571634776)
(include meta-analysis,2.3513752571634776)
(agent functional,2.3513752571634776)
(diagnostic evaluation,2.3513752571634776)
(vegf family,2.3513752571634776)
(require contrast,2.3513752571634776)
(her2 positive,2.3513752571634776)
(background sentence,2.3513752571634776)
(aspirin prescription,2.3513752571634776)
(contrast imaging,2.3513752571634776)
(signature develop,2.3513752571634776)
(treatment risk,2.3513752571634776)
(behavior identification,2.3513752571634776)
(probe demonstrate,2.3513752571634776)
(indicate potential,2.3513752571634776)
(high-risk model,2.3513752571634776)
(include case,2.3513752571634776)
(live sister,2.3513752571634776)
(inhibitor target,2.3513752571634776)
(lesion persistent,2.3513752571634776)
(therapeutic approach,2.3513752571634776)
(cardiac ejection,2.3513752571634776)
(multispectral optoacoustic,2.3513752571634776)
(drain place,2.3513752571634776)
(perform dual,2.3513752571634776)
(minimal silver,2.3513752571634776)
(glycosylation membrane,2.3513752571634776)
(approach view,2.3513752571634776)
(familial cancer,2.3513752571634776)
(evaluation management,2.3513752571634776)
(cancer easily,2.3513752571634776)
(management plan,2.3513752571634776)
(method lead,2.3513752571634776)
(nanoparticle multimodal,2.3513752571634776)
(risk shape,2.3513752571634776)
(silver sulfide,2.3513752571634776)
(investigate modality,2.3513752571634776)
(treatment lead,2.3513752571634776)
(directly regulate,2.3513752571634776)
(high cost,2.3513752571634776)
(probe 68ga-pentixafor,2.3513752571634776)
(mri examination,2.3513752571634776)
(diagnostic sensitivity,2.3513752571634776)
(misdiagnosis human,2.3513752571634776)
(anthracycline common,2.3513752571634776)
(risk perception,2.3513752571634776)
(adjustment body,2.3513752571634776)
(month diagnosis,2.3513752571634776)
(introduce shorten,2.3513752571634776)
(result thirteen,2.3513752571634776)
(method comprehensive,2.3513752571634776)
(malignancy older,2.3513752571634776)
(method paper,2.3513752571634776)
(presentation conclusion,2.3513752571634776)
(mouse liver,2.3513752571634776)
(response symptom,2.3513752571634776)
(crucial application,2.3513752571634776)
(bet protein,2.3513752571634776)
(concern concurrently,2.3513752571634776)
(target specific,2.3513752571634776)
(image case,2.3513752571634776)
(people higher,2.3513752571634776)
(component vegf,2.3513752571634776)
(spectrometry glycosylation,2.3513752571634776)
(radiotherapy unresected,2.3513752571634776)
(discuss review,2.3513752571634776)
(performance cxcr4-directed,2.3513752571634776)
(retrospective study,2.3513752571634776)
(gadolinium-based contrast,2.3513752571634776)
(strong contrast,2.3513752571634776)
(interval association,2.3513752571634776)
(spite therapeutic,2.3513752571634776)
(metastasis aim,2.3513752571634776)
(follow-up month,2.3513752571634776)
(develop component,2.3513752571634776)
(colon cancer,2.3513752571634776)
(special type,2.3513752571634776)
(intravenous administration,2.3513752571634776)
(confirm tnbc,2.3513752571634776)
(survival discovery,2.3513752571634776)
(subgroup validate,2.3513752571634776)
(radiology rise,2.3513752571634776)
(case metastatic,2.3513752571634776)
(injury diagnosis,2.3513752571634776)
(observe conclusion,2.3513752571634776)
(enable effective,2.3513752571634776)
(unresectable follow,2.3513752571634776)
(mammography mammography,2.3513752571634776)
(protocol feasible,2.3513752571634776)
(dye serve,2.3513752571634776)
(gene editing,2.3513752571634776)
(pathological prognostic,2.3513752571634776)
(patient month,2.3513752571634776)
(lesion importantly,2.3513752571634776)
(addition long,2.3513752571634776)
(treatment method,2.3513752571634776)
(error computer,2.3513752571634776)
(reson imaging,2.3513752571634776)
(inclusion criterion,2.3513752571634776)
(find previous,2.3513752571634776)
(wild-type tnbc,2.3513752571634776)
(perceive personal,2.3513752571634776)
(accumulate dose,2.3513752571634776)
(early detectionof,2.3513752571634776)
(woman develop,2.3513752571634776)
(study study,2.3513752571634776)
(diagnose serve,2.3513752571634776)
(adenoma acromegaly,2.3513752571634776)
(report stage,2.3513752571634776)
(mutation brca1,2.3513752571634776)
(mode interestingly,2.3513752571634776)
(previous decade,2.3513752571634776)
(report rare,2.3513752571634776)
(unresected locally,2.3513752571634776)
(breast dce-mri,2.3513752571634776)
(discomfort aim,2.3513752571634776)
(extent duration,2.3513752571634776)
(modality demonstrate,2.3513752571634776)
(breast tomosynthesis,2.3513752571634776)
(cancer include,2.3513752571634776)
(mass modified,2.3513752571634776)
(apparent increase,2.3513752571634776)
(surgical excision,2.3513752571634776)
(ulceration bleed,2.3513752571634776)
(inhibitor microrna,2.3513752571634776)
(personalistic personal,2.3513752571634776)
(primary recurrent,2.3513752571634776)
(exclude seroma,2.3513752571634776)
(feature extract,2.3513752571634776)
(require investigation,2.3513752571634776)
(lung colon,2.3513752571634776)
(number remove,2.3513752571634776)
(ten study,2.3513752571634776)
(month complete,2.3513752571634776)
(easily distinguish,2.3513752571634776)
(effort develop,2.3513752571634776)
(phase directionality,2.3513752571634776)
(danish breast,2.3513752571634776)
(high dose,2.3513752571634776)
(receive dose,2.3513752571634776)
(resonance imaging,2.3513752571634776)
(level relate,2.3513752571634776)
(thirteen patient,2.3513752571634776)
(radiotherapy tumour,2.3513752571634776)
(aspirin cbc,2.3513752571634776)
(invariance wavelet,2.3513752571634776)
(time maintain,2.3513752571634776)
(cost concept,2.3513752571634776)
(accumulation evaluate,2.3513752571634776)
(population article,2.3513752571634776)
(image harmfulor,2.3513752571634776)
(her2 expression,2.3513752571634776)
(rad51 level,2.3513752571634776)
(detect cancercell,2.3513752571634776)
(phantom imaging,2.3513752571634776)
(applicable case,2.3513752571634776)
(imaging protocol,2.3513752571634776)
(experience high-dose,2.3513752571634776)
(place breast,2.3513752571634776)
(compound clinic,2.3513752571634776)
(associate improved,2.3513752571634776)
(peptide infrare,2.3513752571634776)
(long scan,2.3513752571634776)
(breast mri,2.3513752571634776)
(define time-varying,2.3513752571634776)
(transform propose,2.3513752571634776)
(cancer centre,2.3513752571634776)
(property improve,2.3513752571634776)
(cancer diagnose,2.3513752571634776)
(diagnosis patient,2.3513752571634776)
(variable molecular,2.3513752571634776)
(base presence,2.3513752571634776)
(highly sensitive,2.3513752571634776)
(limitation abbreviate,2.3513752571634776)
(play major,2.3513752571634776)
(preliminary molecular,2.3513752571634776)
(tumor imaging,2.3513752571634776)
(harmfulor harmless,2.3513752571634776)
(regard cancer,2.3513752571634776)
(phenotype brca1,2.3513752571634776)
(accuracy effort,2.3513752571634776)
(82.5 multivariate,2.3513752571634776)
(receptor positive,2.3513752571634776)
(inhibitory therapy,2.3513752571634776)
(screening breast,2.3513752571634776)
(vitamin intake,2.3513752571634776)
(systemic review,2.3513752571634776)
(petct image,2.3513752571634776)
(record result,2.3513752571634776)
(substantial variation,2.3513752571634776)
(report 15.3,2.3513752571634776)
(cost mri,2.3513752571634776)
(surgical approach,2.3513752571634776)
(ion release,2.3513752571634776)
(identify woman,2.3513752571634776)
(agent seek,2.3513752571634776)
(simplify diagnosis,2.3513752571634776)
(higher proportion,2.3513752571634776)
(develop apply,2.3513752571634776)
(tool promise,2.3513752571634776)
(receptor her2,2.3513752571634776)
(describe multiple,2.3513752571634776)
(potent dem,2.3513752571634776)
(associate increase,2.3513752571634776)
(outcome record,2.3513752571634776)
(respondent tend,2.3513752571634776)
(underutilize perceive,2.3513752571634776)
(study confirm,2.3513752571634776)
(prediagnosis dietary,2.3513752571634776)
(study role,2.3513752571634776)
(patient meet,2.3513752571634776)
(filter shearlet,2.3513752571634776)
(levonorgestrel intrauterine,2.3513752571634776)
(conventional imaging,2.3513752571634776)
(disease surveillance,2.3513752571634776)
(induction epigenetic,2.3513752571634776)
(heterogeneous disease,2.3513752571634776)
(biomarker cardiotoxicity,2.3513752571634776)
(currently contrast,2.3513752571634776)
(high suspicion,2.3513752571634776)
(long term,2.3513752571634776)
(prolactinoma young,2.3513752571634776)
(status family,2.3513752571634776)
(desquamation experience,2.3513752571634776)
(component develop,2.3513752571634776)
(persistent low,2.3513752571634776)
(node nac,2.3513752571634776)
(sensitive tumor-specific,2.3513752571634776)
(response treatment,2.3513752571634776)
(risk malignancy,2.3513752571634776)
(tumour remain,2.3513752571634776)
(analysis reveal,2.3513752571634776)
(vivo compare,2.3513752571634776)
(conclusion study,2.3513752571634776)
(magnetic resonance,2.3513752571634776)
(signal intensity,2.3513752571634776)
(higher resolution,2.3513752571634776)
(technical efficacy,2.3513752571634776)
(genetic counseling,2.3513752571634776)
(apoptosis cell,2.3513752571634776)
(receive anthracycline,2.3513752571634776)
(change decade,2.3513752571634776)
(imaging 2018,2.3513752571634776)
(relationship brd4,2.3513752571634776)
(course her2,2.3513752571634776)
(troponin high,2.3513752571634776)
(repair explore,2.3513752571634776)
(mri continue,2.3513752571634776)
(resolution risk,2.3513752571634776)
(advance screen,2.3513752571634776)
(gene-expression-based signature,2.3513752571634776)
(breast chest,2.3513752571634776)
(factor molecular,2.3513752571634776)
(indicative benign,2.3513752571634776)
(offer screening,2.3513752571634776)
(imaging evidence,2.3513752571634776)
(predict outcome,2.3513752571634776)
(towavelet filter,2.3513752571634776)
(severe cardiotoxicity,2.3513752571634776)
(pattern low-dose,2.3513752571634776)
(fluorescent osteopontin,2.3513752571634776)
(pet find,2.3513752571634776)
(mode establish,2.3513752571634776)
(identify newly,2.3513752571634776)
(proportional hazard,2.3513752571634776)
(detail ondata,2.3513752571634776)
(gene dna,2.3513752571634776)
(develop moist,2.3513752571634776)
(treatment outcome,2.3513752571634776)
(imaging osteopontin-based,2.3513752571634776)
(susceptibility prolactinoma,2.3513752571634776)
(signature higher,2.3513752571634776)
(detectable 68ga-pentixafor,2.3513752571634776)
(receptor human,2.3513752571634776)
(thematic analysis,2.3513752571634776)
(subtype-specific signature,2.3513752571634776)
(study require,2.3513752571634776)
(modified factor,2.3513752571634776)
(life result,2.3513752571634776)
(woman dense,2.3513752571634776)
(sensitivity woman,2.3513752571634776)
(kidney liver,2.3513752571634776)
(imaging facilitate,2.3513752571634776)
(receptor overexpress,2.3513752571634776)
(cancer causation,2.3513752571634776)
(imaging cornerstone,2.3513752571634776)
(cardiotoxicity require,2.3513752571634776)
(type surgery,2.3513752571634776)
(find correlation,2.3513752571634776)
(positive patient,2.3513752571634776)
(survival inconsistent,2.3513752571634776)
(theory inheritance,2.3513752571634776)
(symptom review,2.3513752571634776)
(perform patient,1.9459101490553132)
(survival survival,1.9459101490553132)
(retrospective analysis,1.9459101490553132)
(review experience,1.9459101490553132)
(median follow-up,1.9459101490553132)
(cancer surgery,1.9459101490553132)
(fluorescence imaging,1.9459101490553132)
(risk factor,1.9459101490553132)
(better understanding,1.9459101490553132)
(risk stratification,1.9459101490553132)
(x-ray mammography,1.9459101490553132)
(method retrospective,1.9459101490553132)
(family history,1.9459101490553132)
(female patient,1.9459101490553132)
(growth factor,1.9459101490553132)
(confidence interval,1.9459101490553132)
(disease diagnosis,1.9459101490553132)
(direct relationship,1.9459101490553132)
(lung cancer,1.9459101490553132)
(preventive strategy,1.9459101490553132)
(cancer breast,1.9459101490553132)
(common cancer,1.9459101490553132)
(aim study,1.9459101490553132)
(patient unresected,1.9459101490553132)
(cancer common,1.9459101490553132)
(patient report,1.9459101490553132)
(imaging investigate,1.9459101490553132)
(dose-dependent reduction,1.9459101490553132)
(negative breast,1.9459101490553132)
(cohort study,1.9459101490553132)
(ratio confidence,1.9459101490553132)
(recurrent breast,1.9459101490553132)
(prognostic factor,1.9459101490553132)
(patient treat,1.9459101490553132)
(cancer prognosis,1.9459101490553132)
(cancer cell,1.9459101490553132)
(radiotherapy patient,1.9459101490553132)
(dna repair,1.9459101490553132)
(characteristic treatment,1.9459101490553132)
(human epidermal,1.9459101490553132)
(study breast,1.9459101490553132)
(breast surgery,1.9459101490553132)
(dna damage,1.9459101490553132)
(diagnosis breast,1.9459101490553132)
(factor receptor,1.9459101490553132)
(epidermal growth,1.9459101490553132)
(detection breast,1.9459101490553132)
(analyze multi-omic,1.9459101490553132)
(clinical trial,1.9459101490553132)
(history breast,1.9459101490553132)
(receptor status,1.9459101490553132)
(damage repair,1.9459101490553132)
(validate clinical,1.9459101490553132)
(agent breast,1.9459101490553132)
(approach breast,1.9459101490553132)
(risk breast,1.6582280766035324)
(cancer woman,1.6582280766035324)
(triple negative,1.6582280766035324)
(estrogen receptor,1.6582280766035324)
(lymph node,1.6582280766035324)
(diagnosis treatment,1.6582280766035324)
(cancer risk,1.6582280766035324)
(cancer diagnosis,1.4350845252893227)
(breast cancer,0.0)
